Navigation Links
World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester

than Grigg Professor of Paediatric Respiratory and Environmental Medicine Institute of Cell and Molecular Science, Queen Mary University London Tel: 020 78822206

Dr Marcus Cooke, Radiation and Oxidative Stress Section Dept. Cancer Studies & Dept. Genetics University of Leicester Tel: 0116 2525825

ISSUED BY:

Ather Mirza Director of Press and Publications University of Leicester University Road Leicester LE1 7RH tel: 0116 252 3335 email: pressoffice@le.ac.uk Looking for an expert? Try http://www.le.ac.uk/press/experts/intro.html UNIVERSITY OF LEICESTER - A member of the 1994 Group of universities that share a commitment to research excellence, high quality teaching and an outstanding student experience. * England's top ranked University for teaching quality and overall satisfaction amongst universities teaching full time students - National Student Survey 2005 and 2006 * One of just 19 UK universities to feature in world's top 200- Shanghai Jiao Tong International Index, 2005 and 2006. Ranked as a Top 20 university by The Times Good University Guide. * Short listed Higher Education Institution of the Year - THES awards 2005 and 2006 * Students' Union of the Year award 2005, short listed 2006 Founded in 1921, the University of Leicester has 19,000 students from 120 countries. Teaching in 18 subject areas has been graded Excellent by the Quality Assurance Agency- including 14 successive scores - a consistent run of success matched by just one other UK University. Leicester is world renowned for the invention of DNA Fingerprinting by Professor Sir Alec Jeffreys and houses Europe's biggest academic Space Research Centre. 90% of staff are actively engaged in high quality research and 13 subject areas have been awarded the highest rating of 5* and 5 for research quality, demonstrating excellence at an international l
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
2. MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2 Clinical Data at the World Asthma Meeting
3. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
4. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
5. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
7. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
8. Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
9. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
10. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
11. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
Post Your Comments:
(Date:12/4/2009)... Inc. (NYSE Amex: PIP ), a biodefense company ... today the presentation of new data from the Company,s ... Antigen (rPA) based anthrax vaccine is structurally stable and ... and including 55 degrees C. The data were ...
(Date:12/4/2009)... PharmAthene, Inc. (NYSE Amex: PIP ), ... and chemical threats, announced today that the Company ... effectiveness of Valortim® in an inhalation anthrax model ... The data are being presented during an oral ...
(Date:12/4/2009)... 4 Watson Pharmaceuticals, Inc. (NYSE: WPI ... that its subsidiary, Watson Laboratories, Inc.-Florida, filed an Abbreviated ... Drug Administration seeking approval to market its 8mg ramelteon ... by Takeda Pharmaceutical Company Limited. Watson,s 8mg ramelteon ...
Breaking Medicine Technology:PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Janet Sartin Expands Line of Products That Reduce and Conceal Eye Puffiness and Fine Lines 51168 1Janet Sartin Expands Line of Products That Reduce and Conceal Eye Puffiness and Fine Lines 51168 2Janet Sartin Expands Line of Products That Reduce and Conceal Eye Puffiness and Fine Lines 51168 3ONRAD Announces New PACS Application Service Provider Model 51165 1ONRAD Announces New PACS Application Service Provider Model 51165 22 reproductive factors are important predictors of death from ovarian cancer 9184 12 reproductive factors are important predictors of death from ovarian cancer 9184 22 reproductive factors are important predictors of death from ovarian cancer 9184 3
... 04, 2007 /PRNewswire-FirstCall/ --,Genta Incorporated announced the ... trial of its marketed product, Ganite(R) (gallium,nitrate ... patients with relapsed or refractory non-Hodgkin's,lymphoma (NHL). ... meeting of,the American Society of Clinical Oncology ...
... Pertuzumab shows promising results in,advanced breast cancer ... BASEL, Switzerland, June 4, 2007-Early clinical results ... medicine pertuzumab, a HER,dimerisation inhibitor, show substantial ... breast cancer, when,combined with Herceptin. The study ...
Other Medicine Technology:Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 2Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 3Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 4Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 5
(Date:12/7/2009)... ORLEANS, Dec. 7 Cell Therapeutics, Inc. ... Ruth Pettengell, M.D. of St. George,s Hospital, University ... American Society of Hematology ("ASH") Annual Meeting updated ... 301) clinical trial of pixantrone (the "PIX 301 ... lymphoma ("NHL") patients who have failed 2 ...
(Date:12/6/2009)... Pharmacyclics, Inc. (Nasdaq: PCYC ) ... study showing safety and clinical activity in patients ... with its HDAC inhibitor PCI-24781 as a single ... 51st ASH Annual Meeting being held in New ... is an oral pan-HDAC inhibitor which is currently ...
(Date:12/6/2009)... in virus , , SUNDAY, Dec. 6 (HealthDay News) -- Early ... in a tiger that lived thousands or millions of years ... took on a bit of a tiger,s genetic material, scientists ... virus to this day. That tiger, in fact, may have ... that ultimately led to its infection of humans. , The ...
(Date:12/6/2009)... Dec. 6, 2009 A new study provides welcome ... as venous thromboembolism (VTE). , The condition is ... year, and occurs when an abnormal clot forms in ... pain and swelling. In some cases, the clot may ... the heart to the lungs, causing a potentially fatal ...
(Date:12/5/2009)... 5 There have been significant scientific advances in ... to gain a better understanding of how certain diseases ... provide patients with the best care. Research presented today ... of Hematology explores optimal induction therapies for managing multiple ...
Breaking Medicine News(10 mins):Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:AIDS May Date Back to Ancient Tiger 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8
... American Society of Aesthetic Plastic Surgery indicate a ... including injectable treatments like BOTOX® Cosmetic and major ... since collection of the data began in 1997. ... a number of these popular options, and Beverly ...
... 24 World Veterinary Day, April 25, 2009, celebrates ... year,s theme, ,Veterinarians and Livestock Farmers: a ... highlights a discipline of veterinary medicine the AVMA ... W. Ron DeHaven, DVM, MBA, Chief Executive Officer of ...
... Inc. announces the completion of its transformation from a telemedicine device ... , ... North Chelmsford, MA (PRWEB) April 24, 2009 ... to a Telemedicine Encounter Management Systems company. AMD will showcase ...
... how business and medicine can collaborate to solve today,s ... questions regarding the state of collaboration between industry, academia ... how evolving reimbursement practices are changing what it means ... 30, 2009, 3:00 6:45 p.m. , PLACE: , Weill ...
... study finds , , FRIDAY, April 24 (HealthDay News) -- ... disease are taking the recommended combination of medications to ... on 711 people with peripheral artery disease who had ... in 2004. Three years later, 465 of the surviving ...
... the virus is the same that sickened seven people in ... officials took extraordinary steps Friday to try to contain a ... and possibly dozens more, and sickened more than 900 other ... that it could mark the start of a flu pandemic, ...
Other Medicine News:Health News:Beverly Hills Cosmetic Plastic Surgeon Andrew T. Cohen, MD Helping New Moms Restore their Bodies with a Mommy Makeover 2Health News:Beverly Hills Cosmetic Plastic Surgeon Andrew T. Cohen, MD Helping New Moms Restore their Bodies with a Mommy Makeover 3Health News:AVMA Celebrates World Veterinary Day 2Health News:AMD Global Telemedicine Inc. to Unveil New Solutions at ATA 2009 Conference in Las Vegas 2Health News:With Peripheral Artery Disease, Med Adherence Is Low 2Health News:At Least 20 Dead, Hundreds Ill in Swine Flu Outbreak in Mexico 2Health News:At Least 20 Dead, Hundreds Ill in Swine Flu Outbreak in Mexico 3Health News:At Least 20 Dead, Hundreds Ill in Swine Flu Outbreak in Mexico 4Health News:At Least 20 Dead, Hundreds Ill in Swine Flu Outbreak in Mexico 5
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 8 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 19.0 mm and length 21 mm....
... The BacT/Alert 3D Signature is ... microbial detection system that integrates blood, ... It is a powerful microbiology workstation ... for higher volume identification and where ...
Medicine Products: